🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Sacituzumab tirumotecan

Also listed in trial records as SKB264
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 60 trials in our China, USA, UK, Ireland and India registers that name Sacituzumab tirumotecan as an intervention. Synced 24 Sep 2026
60Trials tracked
33Recruiting now
20Lead sponsors
5Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards

Sacituzumab tirumotecan is named as a drug or biological intervention in 60 clinical trials in our China, USA, UK, Ireland and India trial registers, 33 of which are recruiting. Lead sponsors include Merck Sharp & Dohme LLC (26), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (7) and Fudan University (5). Registered phases: Phase 2, Phase 3, Phase 1/2, Not applicable and Observational. Conditions studied include Esophageal Squamous Cell Carcinoma; Cervical Cancer; Non-small Cell Lung Cancer (NSCLC).

01

Clinical trials of Sacituzumab tirumotecan

60 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06170788 Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer (NSCLC)
 Phase 3 Recruiting Merck Sharp & Dohme LLC UK, USA, China
NCT06279364 A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (ClinicalTrials.gov ↗)
Triple Negative Breast Cancer
 Phase 3 Recruiting Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. China
NCT06312137 A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (ClinicalTrials.gov ↗)
Non Small Cell Lung Cancer
 Phase 3 Recruiting Merck Sharp & Dohme LLC UK, USA, China
NCT06312176 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (ClinicalTrials.gov ↗)
Breast Neoplasms
 Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA, India
NCT06393374 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) (ClinicalTrials.gov ↗)
Triple-Negative Breast Cancer
 Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA
NCT06824467 A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
 Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA
NCT06841354 A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (ClinicalTrials.gov ↗)
Triple Negative Breast Neoplasms
 Phase 3 Recruiting Merck Sharp & Dohme LLC UK, USA, China
NCT06952504 A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) (ClinicalTrials.gov ↗)
Endometrial Cancer
 Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT06966700 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (ClinicalTrials.gov ↗)
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
 Phase 3 Recruiting Merck Sharp & Dohme LLC UK, USA, India, China
NCT07216703 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (ClinicalTrials.gov ↗)
Cervical Cancer
 Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA, India
NCT07318558 A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Ovarian Neoplasms, Ovarian Cancer
 Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA
NCT07419295 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Bladder Cancer
 Phase 3 Recruiting Merck Sharp & Dohme LLC UK, USA, China
NCT06788912 Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) (ClinicalTrials.gov ↗)
Lung Neoplasm Malignant
 Phase 2 Recruiting Merck Sharp & Dohme LLC USA
NCT07182721 SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment (ClinicalTrials.gov ↗)
HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264, Inetetamab
 Phase 2 Recruiting Fudan University China
NCT07252739 KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (ClinicalTrials.gov ↗)
Malignant Neoplasm
 Phase 2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT07256236 SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer (ClinicalTrials.gov ↗)
Cervical Cancer
 Phase 2 Recruiting Fujian Cancer Hospital China
NCT07324629 Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma (ClinicalTrials.gov ↗)
Thymic Carcinoma
 Phase 2 Recruiting Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. China
NCT07371208 Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 2 Recruiting Shanghai Jiao Tong University School of Medicine China
NCT07375316 A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy (ClinicalTrials.gov ↗)
Non Small Cell Lung Cancer
 Phase 2 Recruiting Guangdong Association of Clinical Trials China
NCT07548060 A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy (ClinicalTrials.gov ↗)
NSCLC Stage IV, EGFR Gene Mutation
 Phase 2 Recruiting Tianjin Medical University Cancer Institute and Hospital China
NCT07623577 Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases (ClinicalTrials.gov ↗)
TNBC, Brain Metastasis
 Phase 2 Recruiting Fudan University China
NCT07697586 SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
NSCLC
 Phase 2 Recruiting Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. China
NCT07811752 Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer (ClinicalTrials.gov ↗)
Esophageal Squamous Cell Carcinoma
 Phase 2 Recruiting Shanghai Chest Hospital China
NCT05319730 A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT06428409 A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) (ClinicalTrials.gov ↗)
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC UK, USA, China
NCT06445972 Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (ClinicalTrials.gov ↗)
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT06469944 Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (ClinicalTrials.gov ↗)
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT06637423 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Non-Muscle Invasive Bladder Cancer
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC UK, USA
NCT06780111 Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (ClinicalTrials.gov ↗)
Esophageal Squamous Cell Carcinoma
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT07286149 A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (ClinicalTrials.gov ↗)
Lung Neoplasm Malignant
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT07586943 SKB118 Injection in Advanced Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumors
 Phase 1/2 Recruiting Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. China
NCT06993506 Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer (ClinicalTrials.gov ↗)
HER2-negative Breast Cancer, Recurrence, Metastasis
 Observational Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences China
NCT07068542 Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer (ClinicalTrials.gov ↗)
Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
 Not applicable Recruiting Zhejiang Provincial People's Hospital China
NCT07628504 Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
Adjuvant Drug Therapy
 Phase 3 Not yet open Fudan University China
NCT06706219 Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC (ClinicalTrials.gov ↗)
Non Small Cell Lung Cancer (Stage III)
 Phase 2 Not yet open Hunan Province Tumor Hospital China
NCT07054242 A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC) (ClinicalTrials.gov ↗)
Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
 Phase 2 Not yet open Yantai Yuhuangding Hospital China
NCT07153965 Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer (ClinicalTrials.gov ↗)
Triple Negative Breast Cancer (TNBC), PD-L1 Positive
 Phase 2 Not yet open Tianjin Medical University Cancer Institute and Hospital China
NCT07244926 Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Lung Cancer
 Phase 2 Not yet open Tianjin Medical University Cancer Institute and Hospital China
NCT07314619 Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer (ClinicalTrials.gov ↗)
Platinum-resistant Recurrent Ovarian Cancer (PROC)
 Phase 2 Not yet open The First Affiliated Hospital of Zhengzhou University China
NCT07466927 Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases (ClinicalTrials.gov ↗)
HER2-negative Breast Cancer
 Phase 2 Not yet open Fudan University China
NCT07545213 Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
 Phase 2 Not yet open The Fourth Affiliated Hospital of Zhejiang University School of Medicine China
NCT07662863 Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01) (ClinicalTrials.gov ↗)
Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma
 Phase 2 Not yet open Fudan University China
NCT07701681 Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma (ClinicalTrials.gov ↗)
ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
 Phase 2 Not yet open Sun Yat-sen University China
NCT07729033 A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
Advanced Biliary Tract Cancers
 Phase 2 Not yet open Tianjin Medical University Cancer Institute and Hospital China
NCT07738757 SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies (ClinicalTrials.gov ↗)
Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies
 Phase 2 Not yet open Peking Union Medical College Hospital China
NCT07750704 Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC (ClinicalTrials.gov ↗)
ALK Positive Non-small Cell Lung Cancer
 Phase 2 Not yet open Guangdong Association of Clinical Trials China
NCT07778368 A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma (ClinicalTrials.gov ↗)
Oral Squamous Cell Carcinoma (OSCC)
 Phase 2 Not yet open Shanghai East Hospital China
NCT07823270 Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma (ClinicalTrials.gov ↗)
Esophageal Squamous Cell Carcinoma
 Phase 2 Not yet open Hebei Medical University Fourth Hospital China
NCT07157956 CVL006 Combination Therapy in Advanced Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumor
 Phase 1/2 Not yet open Convalife (Shanghai) Co., Ltd. China
NCT05347134 SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (ClinicalTrials.gov ↗)
Triple Negative Breast Cancer
 Phase 3 Active, closed Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. China
NCT05870319 A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer
 Phase 3 Active, closed Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. China
NCT06074588 Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer (NSCLC)
 Phase 3 Active, closed Merck Sharp & Dohme LLC UK, USA, China
NCT06132958 Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (ClinicalTrials.gov ↗)
Endometrial Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT06305754 Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer (NSCLC)
 Phase 3 Active, closed Merck Sharp & Dohme LLC USA, India, China
NCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (ClinicalTrials.gov ↗)
Gastroesophageal Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC UK, USA, China
NCT06459180 A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cervical Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT06670196 A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Non-Small Cell Lung Cancer
 Phase 3 Active, closed Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. China
NCT05642780 SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors (ClinicalTrials.gov ↗)
Solid Tumor
 Phase 2 Active, closed Klus Pharma Inc. USA, China
NCT04152499 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (ClinicalTrials.gov ↗)
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
 Phase 1/2 Active, closed Klus Pharma Inc. USA, China
NCT06483334 A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
 Phase 1/2 Active, closed Merck Sharp & Dohme LLC UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

69 conditions
Condition (as registered)Trials
Esophageal Squamous Cell Carcinoma4
Cervical Cancer3
Non-small Cell Lung Cancer (NSCLC)3
Ovarian Cancer2
Endometrial Cancer2
Breast Neoplasms2
Metastatic Urothelial Carcinoma2
Bladder Cancer2
Triple Negative Breast Neoplasms2
Non Small Cell Lung Cancer2
Gastroesophageal Junction2
Gastroesophageal Adenocarcinoma2
Esophageal Neoplasms2
Esophageal Cancer2
Lung Neoplasm Malignant2
Urothelial Carcinoma2
Gastric Adenocarcinoma2
Gastroesophageal Junction Adenocarcinoma2
Non-small Cell Lung Cancer2
HER2-negative Breast Cancer2
Triple Negative Breast Cancer2
Ovarian Neoplasms1
Fallopian Tube Cancer1
Primary Peritoneal Cancer1
Triple-Negative Breast Cancer1
Locally Advanced Urothelial Carcinoma1
Non-Muscle Invasive Bladder Cancer1
Gastroesophageal Cancer1
Colorectal Cancer1
Pancreatic Ductal Adenocarcinoma1
Biliary Tract Cancer1
HR Low-Positive/HER2-Negative Breast Neoplasms1
Malignant Neoplasm1
Adjuvant Drug Therapy1
Advanced Biliary Tract Cancers1
TNBC1
Brain Metastasis1
NSCLC Stage IV1
EGFR Gene Mutation1
Triple Negative Breast Cancer (TNBC)1

+ 29 more conditions in the trial records above.

03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Merck Sharp & Dohme LLC26
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.7
Fudan University5
Tianjin Medical University Cancer Institute and Hospital4
Guangdong Association of Clinical Trials2
Klus Pharma Inc.2
Shanghai Chest Hospital1
Yantai Yuhuangding Hospital1
Hebei Medical University Fourth Hospital1
Fujian Cancer Hospital1
Sun Yat-sen University1
The First Affiliated Hospital of Zhengzhou University1
Peking Union Medical College Hospital1
Shanghai East Hospital1
Hunan Province Tumor Hospital1
Zhejiang Provincial People's Hospital1
The Fourth Affiliated Hospital of Zhejiang University School of Medicine1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
Shanghai Jiao Tong University School of Medicine1
Convalife (Shanghai) Co., Ltd.1
04

Trials by country register

RegisterSacituzumab tirumotecan trials
Clinical trials in China52
Clinical trials in USA28
Clinical trials in UK18
Clinical trials in Ireland8
Clinical trials in India4

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sacituzumab tirumotecan works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sacituzumab tirumotecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.